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ABSTRACT
Multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and develop-
ing countries. The prevalence of drug resistance in Mycobacterium tuberculosis (MTB) isolates (n=692) from 
Mpumalanga province was assessed. In total, 692 (64%) MTB strains from cases with pulmonary TB were 
tested for susceptibility against rifampicin, isoniazid, ethambutol, and streptomycin using the MGIT 960 
instrument. Two hundred and nine (30.2%) strains were resistant to one or more drugs. Resistance to one 
drug ranged from 1.4% for ethambutol to 17.7% for rifampicin. The prevalence of MDR-TB ranged from 
6.7% for three drugs to 34% for four drugs, with significant predictors being patients’ age-groups of 25-54 
years (p=0.0012) and >55 years (p=0.007). The result showed a high level (58.4%) of MDR-TB from cases 
in Mpumalanga province. To achieve a higher cure rate in this province, drug-susceptibility tests must be 
done for every case. 
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INTRODUCTION
Tuberculosis (TB) remains a deadly infectious dis-
ease, affecting millions of people worldwide. Al-
though it is a global epidemic, TB predominantly 
affects populations in resource-poor countries, 
where 98% of all deaths due to TB occur (1). World-
wide, two billion people are latently infected with 
Mycobacterium tuberculosis (MTB). In 2005, 8.9 mil-
lion new cases of TB were recorded, and 1.8 million 
deaths were attributed to the disease (2,3). Accord-
ing to the World Health Organization (WHO), there 
were an estimated 500,000 cases of MDR-TB in 2007 
(4). It is estimated that the actual number of new 
cases is three times the number of cases reported 
(5). One-third of 40 million people currently infect-
ed with human immunodeficiency virus (HIV) are 
co-infected with TB (6,7). The changing patterns of 
global health events over the last two decades, par-
ticularly the spread of HIV and drug-resistant TB, 
have aided in posing serious healthcare problems, 
thus necessitating the advancement of alternative 
strategies for effectively combating these re-emerg-
ing problems. Strains of MTB resistant to anti-my-
cobacterial agents, including isoniazid (INH) and 
rifampicin (RIF), with or without resistance to other 
first-line drugs, have been reported worldwide (8). 
Recently-described extensively drug-resistant TB 
(XDR-TB) has been reported in South Africa (9-11).   
The WHO recommends standardized TB treatment 
regimens based on short-course chemotherapy. 
The anti-TB drug regimen recommended for the 
treatment of new cases consists of two months 
of INH, RIF, pyrazinamide (PZA), and ethambu-
tol (EMB) administration, followed by four months 
of INH and RIF (12). This treatment is usually ef-
fective against wild MTB strains that have never 
been exposed to anti-TB drugs for more than 30 
days (13). The most common indicator of drug-Green E et al. Drug-susceptibility patterns of Mycobacterium tuberculosis in South Africa
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resistant (DR) and multidrug-resistant tuberculosis 
(MDR-TB) is a history of incorrect treatment of TB 
(14,15).  
Continuous surveillance of primary (infection with 
a drug-resistant strain) and secondary drug resis-
tance (selection and growth of resistant popula-
tion) patterns of MTB is important in assessing the 
efficacy of chemotherapy regimens used in the past 
years and in detecting the problems in past treat-
ments (16). Attention has focused on assessing the 
global burden of MDR-TB and predicting the future 
threat of this pathogen. Some investigators predict 
a global pandemic of MDR-TB whereas others see it 
as a local problem that can be managed by properly 
implementing the currently-recommended strate-
gies (14). Despite this attention, there is little con-
sensus on either the magnitude of the problem or 
its future trend.
There is a paucity of information in primary drug 
resistance among MTB strains circulating in Mpum-
alanga province, South Africa. The present study 
was, therefore, undertaken to measure the preva-
lence of DR-TB, including MDR-TB, in Mpumalan-
ga province. These results will contribute to guid-
ing the design of retreatment regimen for DR-TB 
and MDR-TB in the province. 
MATERIALS AND METHODS
Study population
One thousand and eighty-four sputum samples 
were collected from 18 districts in Mpumalanga 
province, South Africa. The inclusion criteria for 
collecting sputum specimens from patients were 
according to the Department of Health guidelines, 
which include clinically-suspected TB, treatment 
failure, and retreatment among patients. Patients, 
aged 15-71, years presenting to different clinics and 
hospitals and outpatient facilities in Mpumalanga 
during January 2004–December 2006 were eligible 
for the study. Informed consent was obtained from 
all patients before enrollment. The Research and 
Ethics Committee of the University of Venda and 
the Department of Health and Welfare, Mpuma-
langa province, approved the study.
Collection of data and definitions 
Clinical, demographic, and epidemiologic data were 
collected by interviewing patients. Demographic 
data included age of patient, gender, region of resi-
dence, and history of treatment. The study focused 
primarily on patients who had positive cultures for 
TB. Multidrug resistance (MDR) was defined as re-
sistance to at least both INH and RIF (17,18) with or 
without resistance to other drugs. Monoresistance 
was defined as resistance exclusively to one of the 
four first-line anti-TB drugs tested (16). Polyresis-
tance was defined as resistance to two or more of 
the four first-line anti-TB drugs but not both INH 
and RIF.
Laboratory methods
Three sputum samples for acid-fast bacillus (AFB) 
smear microscopy and culture were obtained from 
each patient enrolled in the study. Specimens were 
obtained at each district and then transported to 
TB Laboratory of Dr George Mukhari Hospital in 
Pretoria where AFB cultures were performed in the 
BacT/Alert 3D system (BA, bioMérieux, Durham, 
USA). Dr George Mukhari Hospital is a 1,200-bed 
tertiary teaching and referral hospital attached to 
the Medunsa Campus of the University of Limpopo. 
Sputum specimens are routinely sent to Microbio- 
logy Laboratory of Dr George Mukhari Hospital for 
analysis of TB. Positive cultures were stained by the 
Ziehl-Neelsen technique. If more than one culture-
positive specimen per patient were processed, only 
one positive result was registered for the patient; 
similarly, if several negative cultures per patient 
were encountered, without a positive finding, only 
one negative result was recorded. Confirmation of 
MTB was done using the AccuProbe DNA hybridi- 
zation assay (GenProbe) following the instructions 
of the manufacturer. All positive cultures were ad-
vanced for susceptibility testing.  
Susceptibility tests
Susceptibility to all culture-positive MTB strains 
was done for the first-line anti-TB drugs, including 
INH, RMP, and EMB and one second-line drug SM 
using the MGIT 960 instrument (Becton Dickinson 
Microbiology Systems, Sparks, MD, USA) (19). The 
concentrations of drugs were 0.2, 40.0, 2.0, and 4.0 
μg/mL for INH, RMP, EMB, and SM respectively. In-
ternal controls were used for ensuring the quality 
of drug-susceptibility test. 
A standard questionnaire and the register were 
used for determining the history of previous anti-
TB drug therapy, and the patients were categorized 
as having either initial or secondary resistance, ac-
cording to the standard definitions (18). Resistance 
to INH and RIF with or without resistance to other 
anti-TB drugs was defined as multidrug resistance.  
Statistical analysis
All statistical analyses were performed using the 
SPSS software (version 16.0) and the Epi Info soft-Green E et al. Drug-susceptibility patterns of Mycobacterium tuberculosis in South Africa
Volume 28 | Number 1 | February 2010 9
ware (version 3.4.1). Risk factors for having non-
multidrug resistance and multidrug resistance 
among culture-confirmed TB cases were assessed. 
Univariate analysis was performed to determine 
unadjusted association of TB drug resistance with 
demographic characteristics of patients. The preva-
lence ratios (PRs) with 95% confidence interval (CI) 
were calculated using StatCalc on Epi Info. A p val-
ue of ≤0.05 was considered statistically significant.
RESULTS
Characteristics of patients
Of the 1,084 sputum specimens received, 692 
(63.8%) were positive for MTB culture. Drug-sus-
ceptibility test and demographic data of the 692 
strains were analyzed (Table 1). The results showed 
that 209 (30.2%) strains were resistant to at least 
one or more drugs. Of the 209 resistant strains, 100 
(47.8%) were isolated from female patients with a 
mean age of 35.08 years while 109 (52.2%) were 
from males with a mean age of 36.70 years. Sev-
enty-two (34.4%) patients were hospitalized, 137 
(65.5%) were outpatients, and eight (3.8%) out-
patients were prisoners. Having a positive culture 
for M. tuberculosis was associated with male gender 
(Table 1). 
Risk of drug-resistant tuberculosis
The prevalence of different patterns of resistance is 
shown in Table 2. Overall, 209 strains were resis-
tant to one or more drugs. The proportion of new 
TB cases with resistance to a single drug ranged 
from 1.4% for EMB to 17.7% for INH, with a me-
dian value of 4.5%. MDR-TB showed a prevalence 
range of 6.7% for INH+RIF+EMB/SM to 34% for 
INH+RIF+SM+EMB, with a median of 14.6%. 
The prevalence of polyresistance to anti-TB drugs 
tested ranged from 0.5% for RIF+SM to 6.7%  for 
INH+SM+EMB (a median of  0.7%) (Table 2). The 
overall resistance to drugs tested ranged from 28% 
for INH to 88% for EMB, with a median of 61%.
There was no significant difference between the 
MDR-TB cases and the non-MDR-TB cases (49%) 
(p=0.6) in male and female cases respectively (Table 
3). A slightly higher prevalence (54%) of MDR-TB 
cases was observed in males than in females (46%). 
However, for the non-MDR-TB cases, a slightly high-
er prevalence (51%) was observed in females than 
in males (49%) (Table 3). The significant predictor 
of MDR-TB in univariate analysis included patients 
aged 35-54 years (prevalence ratio [PR]=1.84, 95% 
CI 1.37-2.46, p value for trends=0.0012) and patients 
aged >54 years (PR=1.55, 95% CI 1.14-2.09, p value 
for trends=0.007) (Table 3).  
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Table 2. Prevalence of first-line anti-tuberculosis 
resistance of 209 Mycobacterium tuberculo-
sis strains from Mpumalanga province
Resistance profile
All cases
No. %
Total  resistance 209 100
Monoresistance 59 28.2
INH only 37 17.7
RIF only 13 6.1
SM only 6 2.9
EMB only 3 1.4
MDR 122 58.4
INH+RIF 23 11
INH+RIF+EMB 14 6.7
INH+RIF+SM 14 6.7
INH+RIF+SM+EMB 71 34
Polyresistance* 28 13.4
INH+SM+EMB 14 6.7
INH+SM 11 5.3
RIF+SM 1 0.5
EMB+SM 2 1
Overall resistant to
INH drug 204 97.6
RIF drugs 136 65.1
SM drugs 119 57
EMB drugs 104 49.8
*Resistant to two or more drugs but not both 
isoniazid and rifampicin; EMB=Ethambutol; 
INH=Isoniazid; MDRTB=Multi-drug-resistant tu-
berculosis (resistant to at least both isoniazid and 
rifampicin with or without resistance to other 
drugs); RIF=Rifampicin; SM=Streptomycin
DISCUSSION
South Africa is one of the 22 high-burden countries 
that contribute approximately 80% of the total 
global burden of all TB cases (7). The country has 
the seventh highest incidence of TB in the world.   
In South Africa, the incidence of TB has increased, 
in parallel to the increase in the estimated preva-
lence of HIV among adults during the past 10 years 
(11), resulting in the increasing recognition of the 
problems posed to public health by TB. The risk 
of DR-TB transmission can be reduced by efficient 
diagnosis and timely treatment of DR-TB patients 
(10). Thus, the DR status of a patient needs to be 
confirmed before treatment. Better access to drug-
susceptibility test results at the time of diagnosis of 
TB would facilitate appropriate selection of treat-
ment regimens, thereby minimizing the develop-
ment of DR strains.  
The main focus in the twentieth century was to 
cure TB and minimize its transmission to other 
persons (20). The WHO developed treatment regi-
men categorized according to different clinical pre-
sentations. Management of new patients suspected 
of having contracted DR strains of M. tuberculosis 
is essentially similar to the treatment of other new 
patients. Standardized treatment regimen (STR) in 
South Africa is given to all patients in a population 
based on the history of drug used in the country 
and a representative drug-susceptibility testing.  
This study indicated monoresistance to all drugs 
tested. Overall, we found that resistance to INH 
(17.7%) and RIF (6.1%) was more prevalent than 
in other agents. The high resistance of MTB to INH 
and RIF—the two main drugs in TB treatment—is 
an alarming sign. In other studies, SM and INH 
have been reported as more common compared 
to the other first-line drugs (21,22). Other patterns 
of anti-TB resistance also existed. In our study, resis-
tance to SM and EMB was less prevalent. Resis-
tance to SM may have been selected following 
previous and regular administration in the treat-
ment of other bacterial diseases. This finding may 
indicate a risk vis-a-vis the use of WHO category II 
(CAT II) regimen for retreatment cases in Mpuma-
langa. About 28.2% and 13.4% of the strains were 
resistant to mono-drug and poly-drugs (non-MDR) 
respectively. Thus, approximately 41.6% of the 
patients in this study needed to have their treat-
ment changed, as the use of standard therapy in 
mono-DR-TB and poly-DR-TB has a high risk of 
failure and can lead to the development of MDR-
TB in these patients (23).
More than half (58.4%) of our study patients were 
infected with MDR strains. This is different from 
what was obtained in Cuba during 1999-2000 
where 0.5% of MDR-TB was obtained (24). The 
relationship between history of receiving anti-TB 
treatment and drug resistance has been clearly des- 
cribed (25). The prevalence of MDR-TB among pa-
tients diagnosed with TB was 16.3% in mid-1990 
(26). In a study conducted in Mpumalanga during 
2004-2006 showed a marked decrease in the preva-
lence of MDR-TB, from 1.92% to 0.7% (27). The dif-
ference could be explained by the criteria used for 
the inclusion of patients in this study. Our sample 
was a convenience sample (patients were requested 
to give the sputum specimen when they were at the 
clinics or hospitals) while the National Department 
of Health did a population-based study. The high 
number of isolated MDR-TB isolates in our study is Green E et al. Drug-susceptibility patterns of Mycobacterium tuberculosis in South Africa
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Table 3. Univariate analysis of association of having MDR-TB with demographic characteristics of patients
Variable
Total resistance 
(n=209)
MDR-TB cases 
(n=122)
Non-MDR-TB 
cases (n=87) PR (95% CI) p value
No. % No. % No. %
Age-group (years)
 15-34 86 41 36 29.5 50 57 1 0.70-1.42 1.00
 35-54 52 25 40 36 12 13 1.84 (1.37-2.46) 0.0012
 55-75 71 34 46 41 25 29 1.55 (1.14-2.09) 0.007
Gender
  Male 109 52 66 54 43 49 1.08 (0.86-1.36) 0.6
  Female 100 48 56 46 44 51 1 0.78-1.28 1.00
CI=Confidence interval; MDR=Multidrug-resistant; PR=Prevalence ratio; TB=Tuberculosis
of concern in Mpumalanga where the TB-control 
programme has not been functioning optimally. In 
general, a high rate of MDR-TB among patients is 
suggestive of poor management of past and exist-
ing disease (27). MDR-TB is associated with higher 
rates of failure and death, is more difficult and ex-
pensive to treat than drug-susceptible TB (7), and 
has an increased risk of adverse drug-effects for pa-
tients (28).  
Knowledge-base for future intervention can be 
provided by identifying risk factors for infection, 
disease, and MDR-TB (29,30). In our study, the 
strongest risk factor of having drug resistance was 
the age-group of 35-44 years and 55-60 years (p< 
0.001). In line with other reports (31,32), the risk 
of MDR-TB was observed in the age-group of 35-54 
years (p=0.0012 at 95% CI) and >54 years (p=0.007 
at CI 95%). These results could be a reflection of 
the 2005 situation when directly-observed therapy, 
short-course strategy (DOTS) was interrupted in 
Mpumalanga (26). Elderly persons had been ex-
posed to the organisms in the past, and during the 
process of treatment, resistance was acquired while 
young patients are more likely to have acquired the 
bacilli more recently when they were more likely 
to be resistant.    
In our study, TB, including MDR-TB, was more 
common among males than among females. Other 
researchers also observed this trend. In a system-
atic review, MDR-TB cases were more likely to be 
associated with males in Western Europe while, in 
Eastern Europe, the male gender was not associated 
with MDR-TB (31,33). It was assumed that the male 
gender could modify the association between treat-
ment and MDR-TB since men are believed to be less 
adherent to treatment than women are.  
The spread of DR-TB in Mpumalanga could serious-
ly hamper efforts to control TB. Limited resources 
and laboratory capacity are a few limitations in the 
proper control of TB. Increasing the laboratory ca-
pacity to deal with DR-TB as recommended by the 
Global Plan to Stop TB and better referral of speci-
mens from patients living in remote areas to re-
gional or national reference laboratories should be 
encouraged to ensure success of the TB-control pro-
gramme and control transmission of DR strains.   
The study encountered some limitations. One of 
these was the potential misclassification of new 
and retreatment cases; some cases registered as new 
may actually have had treatment for TB in the past. 
Classification was based on the patient’s history of 
prior treatment for TB and review of medical re-
cords (which were available for all but four patients 
enrolled). Due to this reason, categorizing the cases 
as new or retreatment was omitted. Our study, car-
ried out at selected sites in Mpumalanga, was not 
population-based, which can introduce bias. The 
high rate of missing data (demographic profile) 
among patients with a negative AFB culture was 
because the study focused primarily on patients 
with a positive culture. However, our study pro-
vides important continual data on drug resistance 
in Mpumalanga. 
Although the sample size is small, the results sug-
gest that multidrug resistance is likely to pose a sig-
nificant threat to health and impede the success of 
TB management in Mpumalanga, if adequate con-
trol measures are not implemented. Monitoring 
the trend of resistance should remain a priority.  
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